HPV to appraise the benefits of HPV vaccination for their health. In order to achieve optimal uptake, vaccine promotion campaigns need to focus on MSM that do not access sexual health clinics and those unwilling to disclose their sexual orientation. O026 HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND STI SCREENING IN MEN WHO HAVE SEX WITH MEN (MSM). CLINICAL OUTCOMES AND FACTORS ASSOCIATED WITH COMPLETION OF A THREE DOSE SCHEDULE WITHIN ONE YEAR IN A CLINICAL COHORT John McSorley*, Eden Gebru, Roubinah Nehor, Andew Shaw, Gary Brook. London North West Healthcare NHS Trust, London, UK 10.1136/sextrans-2016-052718.25 Background/introduction We introduced HPV4 vaccination for younger MSM under 27 years into our sexual health services in 2012. We report on the attendance behaviour, clinical outcomes, completion rates and factors associated with vaccination comple- tion in our cohort. Aims (1) To deliver 3 dose HPV4 vaccination to younger MSM. (2) To increase engagement and STI testing by younger MSM at integrated sexual health services. Methods HPV4 vaccine was offered at Time 0, 2–4 and 6–12 months, with STI testing, clinic call/recall, alongside care and support as appropriate. We conducted a retrospective electronic case note (EPR) review of all eligible MSM at end 2015. Com- pletion rates are censored at 1 year. Results 893/930 (96%) offered vaccine accepted 1 st dose. Discussion/conclusion We observed 3 dose completion rates commensurate with outcomes expected from a catch up vaccina- tion programme. Completion was associated with older age, HIV infection, prior known HPV infection, self-identifying homosexual men and non- white british ethnicities. We observed high rates of STI testing and infection in this cohort. Delivering HPV vaccination within sexual health care services is an effective engagement strategy for young MSM. O027 RAPID FALL IN QUADRIVALENT VACCINE TARGETED HUMAN PAPILLOMAVIRUS GENOTYPES IN HETEROSEXUAL MEN FOLLOWING THE AUSTRALIAN FEMALE HPV VACCINATION PROGRAMME: AN OBSERVATIONAL STUDY FROM 2004 TO 2015 1,2 Eric Chow, 3,4 Dorothy Machalek, 3,4 Sepehr Tabrizi, 3,4 Jennifer Danielewski, 1 Glenda Fehler, 1,2 Catriona Bradshaw, 3,4 Suzanne Garland, 1,2 Marcus Chen, 1,2 Christopher Fairley, 1 Sandra Walker*. 1 Melbourne Sexual Health Centre, Alfred Health, Melbourne, VIC, Australia; 2 Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia; 3 Murdoch Childrens Research Institute, Melbourne, VIC, Australia; 4 Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Parkville, VIC, Australia 10.1136/sextrans-2016-052718.26 Background/introduction Australia introduced the national quad- rivalent human papillomavirus (4vHPV) vaccination programme in April 2007 in young women and included young boys in Feb 2013. Aim(s)/objectives To examine the prevalence of 4vHPV and the nine-valent (9vHPV) targeted vaccines genotypes among pre- dominantly unvaccinated heterosexual men in Australia in 2004– 2015. Methods 1,466 young heterosexual men tested positive for Chla- mydia trachomatis were included. We calculated the prevalence of any HPV genotypes, genotypes 6/11/16/18 in the 4vHPV, and five additional genotypes 31/33/45/52/58 in the 9vHPV, detected in urine or urethral swab samples over each year stratified by country of birth. Results The 4vHPV genotypes decreased from 20% in 2004/05 to 3% in 2014/15 (p trend < 0.001) among Australian-born men; and a greater decline was observed in Australian-born men aged £21 (from 31% to 0%; p trend < 0.001) in the last 11 years. No trends were observed in any HPV genotypes or in HPV 31/33/ 45/52/58. There was a decline in HPV 16/18 (p = 0.004) but not in HPV 6/11 (p = 0.172) in the post-vaccination period among men who recently arrived in Australia from countries with a bivalent vaccine programme. No change in 4vHPV in men from countries without any HPV vaccine programme. Discussion/conclusion The marked reduction in prevalence of 4vHPV genotypes among unvaccinated Australian-born men, suggests herd protection from the female vaccination pro- gramme. The decline in HPV 16/18, but not in HPV 6/11 Abstract O026 Table 1 HPV4 vaccination 3 dose completion within 1 year (2015 figures pro rata), STI testing and detection rates 2013 No. (%) 2014 No. (%) 2015 No. (%) STI screen/ Total No. (%) STI +ve/ Total No. (%) STI +ve/ No. Tested (%) Dose 1 239 255 399 880/893(99) 283/893(32) 283/880(32) Dose 2 187(78) 194(76) 243/324(75) 556/658(84) 77/658(12) 77/556(14) Dose 3 148(62) 140(56) 111/200(56) 372/427(87) 60/427(14) 60/372(16) Factors associated with 3 doses in 1yr No.s/Total (%) No.s/Total (%) p value BOLD indicates higher completion Age <21yrs 57/119 (48) >21yrs 232/375 (62) p = 0.008 HIV status HIV -ve 228/420 (54) HIV +ve 61/74 (82) p = 0.0001 Prior HPV Yes 41/57 (72) No 248/438 (56) p = 0.03 Orientation H* 231/379 (61) Bis* 38/77 (49) p = 0.02 Ethnic Group WB* 81/172 (47) WO* 66/102 (65) p = 0.006 Asian* 65/98 (66) p = 0.003 Black* 54/80 (68) p = 0.003 *H = Homosexual, Bis = Bisexual, WB = white British, WO = white Other, Asian = All asian ethnicities, Black = All black ethnicities by UK Census Ethnicity categories Abstracts A10 Sex Transm Infect 2016;92(Suppl 1):A1–A106